The American company Moderna which is already in Phase III of testing its COVID vaccine — where they actually test the vaccine on humans — has just released results which prove that older participants who receive the doses also produce a strong immune response.
This is critical because the immune system weakens with age, so the fact that this new vaccine will work for people most at risk for the disease is welcome news.
By tricking the body into s producing high levels of neutralizing antibodies and T-cells, the vaccine defeats the COVID proteins.
Reminder: Moderna has a $1.5 billion supply agreement with the US to produce 100 million doses.
